Scholarlink

<p>Current guidelines on treatment of metastatic renal cell carcinoma (mRCC) suggest an emerging role of local therapy (LT). Still there is a lack of data which patients may benefit from additional LT once medical treatment (MT) is initiated. We retrospectively aim to characterize LT in patients with mRCC who underwent LT while receiving MT. 315/401 mRCC patients were eligible, thereof 163 (51.7%) received LT during MT (LT( +)), while 152 (48.3%) received only MT (LT(-)). Radiotherapy (49.1%) and surgery (41.7%) were the most frequently administered LT modalities. Overall survival (OS) was not superior in LT( +) vs. LT(-) (35.9, (95%-CI [confidence interval]: 29.8–42.0) vs. 20.3, (95%-CI: 10.3–30.3) months, log-rank p = 0.117). However, in a subgroup analysis the duration of MT prior to initiation of LT (≤ 6&#xa0;months 24.1 (95%-CI: 18.6–29.6) vs. &gt; 6&#xa0;months: 43.0 (95%-CI: 32.2–36.2) months, log-rank p = 0.005) and the type of progression (oligoprogression: 44.0 (95%-CI: 31.5–56.5) vs. systemic progression: 29.6 (95%-CI: 23.4–35.8) months, log-rank p = 0.03) were associated with improved OS. We present the largest analysis of LT during MT. Our study has enhanced our understanding of LT utilization in mRCC after MT is already initiated. Ultimately, the inclusion of LT could improve OS in selected patients receiving MT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of local therapy in metastatic renal cell carcinoma during medical treatment in a retrospective analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月30日

查看全文
  • Sena Hoffer,
  • Hendrik Eggers,
  • Tabea Fröhlich,
  • Paula Kappler,
  • Maria-Luisa Tiemann,
  • Viktor Grünwald,
  • Christoph Henkenberens,
  • Mohamed Omar,
  • Robert M. Blach,
  • Florian Heidel,
  • Philipp Ivanyi

摘要

Current guidelines on treatment of metastatic renal cell carcinoma (mRCC) suggest an emerging role of local therapy (LT). Still there is a lack of data which patients may benefit from additional LT once medical treatment (MT) is initiated. We retrospectively aim to characterize LT in patients with mRCC who underwent LT while receiving MT. 315/401 mRCC patients were eligible, thereof 163 (51.7%) received LT during MT (LT( +)), while 152 (48.3%) received only MT (LT(-)). Radiotherapy (49.1%) and surgery (41.7%) were the most frequently administered LT modalities. Overall survival (OS) was not superior in LT( +) vs. LT(-) (35.9, (95%-CI [confidence interval]: 29.8–42.0) vs. 20.3, (95%-CI: 10.3–30.3) months, log-rank p = 0.117). However, in a subgroup analysis the duration of MT prior to initiation of LT (≤ 6 months 24.1 (95%-CI: 18.6–29.6) vs. > 6 months: 43.0 (95%-CI: 32.2–36.2) months, log-rank p = 0.005) and the type of progression (oligoprogression: 44.0 (95%-CI: 31.5–56.5) vs. systemic progression: 29.6 (95%-CI: 23.4–35.8) months, log-rank p = 0.03) were associated with improved OS. We present the largest analysis of LT during MT. Our study has enhanced our understanding of LT utilization in mRCC after MT is already initiated. Ultimately, the inclusion of LT could improve OS in selected patients receiving MT.